课题基金 / 基金详情

AMINOSTEROL COMPOUNDS AS THERAPEUTICS FOR ASTHMA

AMINOSTEROL COMPOUNDS AS THERAPEUTICS FOR ASTHMA
氨基甾醇化合物作为哮喘的治疗剂
批准号:
6075001
负责人:
ROY C. LEVITT
金额:
$10.0万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2000
资助国家:
美国
项目状态:
已结题
起止时间:
2000-08-15 至 2001-02-14

项目摘要

项目成果

ROY C. LEVITT的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Asthma is a complex inflammatory disease of the airway. Current treatments employ the use of inhaled bronchodilators and corticosteroids. While these medicines are effective for most cases of asthma, they are less effective in severe forms of the disease. Moreover, the chronic use of corticosteroids has been associated with side effects in a subset of patients. Therefore the development of novel medications that are effective in suppressing the asthmatic response and lack the pharmacological properties of corticosteroids is desirable for the treatment of this disorder. We have identified a novel class of low molecular weight molecules that have potent effects on blocking lymphocyte heterotypic aggregations in vitro. in vivo data suggest that these compounds have potent activity in suppressing asthmatic-like responses to antigen in rodent models of asthma. Using combinatorial approaches and structure activity relationships in vitro, we have developed new analogs of the prototype that have more potent activity in suppressing lymphocyte aggregation in vitro. The aims of this grant are: 1) prepare analytically pure preparations of the aminosterol prototype and its analogs for in vivo toxicity studies; and 2) perform in vivo studies with these compounds to determine their efficacy in suppressing asthmatic-like responses to antigen. PROPOSED COMMERCIAL APPLICATIONS: The use of novel low molecular weight compounds that are able to suppress the asthmatic response to antigen via non-corticosteroidal mechanisms have a broad potential for commercialization as new anti- inflammatory and asthma medicines. It is our intent to pursue the generation and development of these aminosterol compounds as an aerosol or oral medication for the treatment of asthma. Magainin is in a unique position to develop compounds of this class because of our intellectual property position, which is secured by multiple patents that cover composition of matter and their use in a broad range of indications.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Disease Modifying Analgesia with CA8 Gene Therapy
Disease Modifying Analgesia with CA8 Gene Therapy
CA8 Variants: New Mechanisms Underlying Transitions to Persistent Pain Syndromes
CA8 Variants: New Mechanisms Underlying Transitions to Persistent Pain Syndromes
海外基金